Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Denali Therapeutics Inc. (NASDAQ:DNLI) recently reported results from its phase 2/3 HEALEY ALS Platform Trial using DNL343 for the treatment of patients with Amyotrophic Lateral Sclerosis [ALS].

However, Denali recently announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.

For the primary analysis, a total of 186 participants who received DNL343 treatment were compared to 139 participants who ...

The trial was part of the HEALEY ALS Platform Trial initiative currently testing multiple drugs against this disease. The 24-week trial showed that fosigotifator did not meet its primary or ...

Topline results from a phase 2/3 clinical trial showed that an eIF2B agonist ... the small molecule DNL343 was examined in the Healey ALS Platform study, whose primary endpoint was change in ...